Track Rallybio Corporation Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Rallybio Corporation Common Stock RLYB · Stock Open Rallybio Corporation Common Stock in new tab

15.78 USD
P/E
3.41
EPS
4.61
P/B
0.91
ROE
34.52
Beta
-0.77
Loading chart...
Key Metrics
Earnings dateMarch 11, 2027
P/E3.41
EPS4.61
Book Value17.31
Price to Book0.91
% Insiders27.106%
Estimates
Forward P/E-2.91
Forward EPS-5.40

DCF valuation

Model fair value for Rallybio Corporation Common Stock (RLYB)
Result
Sign in to run the valuation for RLYB.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Rallybio Corporation Common Stock Logo Rallybio Corporation Common Stock Analysis (RLYB)

United States Health Care Official Website Stock

Is Rallybio Corporation Common Stock a good investment? Rallybio Corporation Common Stock (RLYB) is currently trading at 15.78 USD.

In terms of valuation, the stock trades at a P/E ratio of 3.41. This relatively low multiple may signal that Rallybio Corporation Common Stock is undervalued compared to historical market norms.

Earnings Schedule: Rallybio Corporation Common Stock is expected to release its next earnings report on March 11, 2027. The market consensus estimate for Forward EPS is -5.40.

Investor FAQ

Does Rallybio Corporation Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Rallybio Corporation Common Stock?

Rallybio Corporation Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 11, 2027. The company currently has a trailing EPS of 4.61.

Company Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

Exchange Ticker
NMS (United States) RLYB
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2026
41.36 USD
Nov. 30, 2026 27.8000
Nov. 13, 2026 13.5600
Upcoming Dividends
Name Payment Date Status Amount
Rallybio Corporation Common Stock Nov 30, 2026 Upcoming 27.8 USD
Rallybio Corporation Common Stock Nov 13, 2026 13.56 USD
Stock Splits
Split Date Split Ratio to 1
Feb. 6, 2026 1:8
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion